<?xml version="1.0" encoding="UTF-8"?>
<Label drug="hydroxychloroquine" track="TAC2017_ADR">
  <Text>
    <Section name="adverse reactions" id="S1">    ADVERSE REACTIONS

      Psychiatric disorders:    Nervousness, emotional lability, psychosis, suicidal behavior.



     Nervous system disorders:    Dizziness, headache, and convulsions have been reported with this class of drugs.



     Eye disorders:    Retinopathy with changes in pigmentation and visual field defects have been reported. In its early form, it appears reversible on discontinuation of hydroxychloroquine. If allowed to develop, there may be a risk of progression even after treatment withdrawal. Cases of maculopathies and macular degeneration have been reported and may be irreversible.



     Skin and subcutaneous tissue disorders:    Bullous eruptions including very rare cases of Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitivity, and exfoliative dermatitis have been reported.
</Section>
    <Section name="boxed warnings" id="S2">

    BOXED WARNING: WARNING

  WARNING

  PHYSICIANS SHOULD COMPLETELY FAMILIARIZE THEMSELVES WITH THE COMPLETE CONTENTS OF THIS LEAFLET BEFORE PRESCRIBING HYDROXYCHLOROQUINE.
</Section>
  </Text>
  <Mentions />
  <Relations />
  <Reactions />
</Label>
